Abizer Gaslightwala - Mar 6, 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Torsten Hombeck, as Attorney-in-Fact
Stock symbol
AKTX
Transactions as of
Mar 6, 2025
Transactions value $
$449,998
Form type
4
Date filed
3/10/2025, 05:00 PM
Previous filing
Feb 7, 2025
Next filing
Mar 24, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKTX American Depositary Shares representing Ordinary Shares Award $150K +134K +281.95% $1.12 181K Mar 6, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKTX Series A Warrants (Right to Buy) Award $150K +134K $1.12 134K Mar 6, 2025 American Depositary Shares representing Ordinary Shares 134K $0.87 Direct F1, F2
transaction AKTX Series B Warrants (Right to Buy) Award $150K +134K $1.12 134K Mar 6, 2025 American Depositary Shares representing Ordinary Shares 134K $0.87 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
F2 On March 6, 2025, the Reporting Person acquired 133,928 ADS and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.